Scholars Central

ArticlePublished 2014

Starting with PD Enables Diversity of Later Treatments

Authors: Hiromichi Suzuki, Hitosi Hoshi, Tsutomu Inoue, Tomohiro Kikuta, Hiroshi Takane, Tsuneo Takenaka, Yumi Kimura

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Various reasons for “Peritoneal Dialysis (PD) First” rather than hemodialysis (HD) have been presented, such as better preservation of residual renal function (RRF), longer survival, and lower incidence of hospitalization. In spite of these advantages for “PD First”, in Japan as well as in the United States the annual rate of patients receiving PD has been reduced to less than 10%. One of the major reasons against selecting PD is that a large proportion of PD patients are transferred from PD to HD in less than 5 years. Our “PD First” policy is based on the diversity of modalities available after discontinuing PD therapy. The purpose of this study was to examine the follow-up of patients who selected “PD First” as the initial treatment of end-stage renal disease (EDRD) between April 1997 and December 2010. Methods: Sex, age, primary underlying diseases and selection of modalities were collected retrospectively. Results: A total of 377 (59.2 ± 8.3 years old; female/male: 255/122) patients were introduced to PD therapy as “PD First.” Patients who were very old, with cardiovascular problems, senile dementia, and neoplasms that were forced to select PD were excluded. One hundred and sixty patients started HD as complementary dialysis therapy and then continued with PD + HD in combination until transfer to HD, transplantation or home HD. Among them, 10 patients received transplants and 22 patients were transferred to home HD. One hundred and twenty eight patients were switched from PD to HD for various reasons. Overall patients’ survival after 5 and 10 years was 84.8% and 55.8%, respectively. Conclusion: Our data shows a diversity of modalities for selection after discontinuing PD therapy alone, as well as providing a rationale to support PD as the initial renal replacement modality for end-stage renal disease patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nephrology & Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Therapeutics
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Hiromichi Suzuki”
  • BylineArticles whose byline prints “Hitosi Hoshi”
  • BylineArticles whose byline prints “Tsutomu Inoue”
  • BylineArticles whose byline prints “Tomohiro Kikuta”
  • BylineArticles whose byline prints “Hiroshi Takane”
  • BylineArticles whose byline prints “Tsuneo Takenaka”
  • BylineArticles whose byline prints “Yumi Kimura”